KEVZARA® (sarilumab) Administration Options
Now you can treat moderate to severe rheumatoid arthritis (RA) with the Kevzara pen and pre-filled syringe which received an Arthritis Foundation ease of use commendation.
KEVZARA (sarilumab) is an injectable prescription medicine called an Interleukin-6 (IL-6) receptor blocker. KEVZARA is used to treat adult patients with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well or could not be tolerated. KEVZARA offers 2 forms of administration for patients: a single dose button-free Pen that is designed to be comfortable to grasp, with an easy-to-remove needle cap, and a single-use syringe. KEVZARA is administered under the skin (subcutaneously) once every 2 weeks, either on its own, or with methotrexate (MTX) or other DMARDs. The following resources are available to reference:
- Detailed medication guide, including prescribing information and risk of serious side effects
- Important safety information
Ease of Use Program
Products Proven to Make Life Easier
The Arthritis Foundation's Ease of Use Certification Program recognizes products proven to make life easier for people who have arthritis and other physical limitations. Independently tested by experts and evaluated by people with arthritis, Ease of Use products are easy to use for everyone.
Learn More About the Ease of Use Program
Stay in the Know. Live in the Yes.
Get involved with the arthritis community. Tell us a little about yourself and, based on your interests, you’ll receive emails packed with the latest information and resources to live your best life and connect with others.